Independence of Lipoprotein(a) and Low-Density Lipoprotein Cholesterol–Mediated Cardiovascular Risk: A Participant-Level Meta-Analysis

H Harpreet S. Bhatia (Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla.) S Simon Wandel (Novartis Pharma AG, Basel, Switzerland (S.W., A.L., K.B.).) P Peter Willeit A Anastasia Lesogor (Novartis Pharma AG, Basel, Switzerland (A.S., A.L.).) K Keith Bailey P Paul M. Ridker (Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (P.M.R.).) P Paul Nestel (Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (P.N.).) J John Simes (NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia (J.S.).) A Andrew Tonkin (School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (A.T.).) G Gregory G. Schwartz (Cardiology Section, Rocky Mountain Regional VA Medical Center and University of Colorado School of Medicine, Aurora, CO (G.G.S.).) H Helen Colhoun (MRC Human Genetics Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics & Molecular Medicine, Edinburgh, UK (H.C.).) C Christoph Wanner S Sotirios Tsimikas

Abstract

BACKGROUND: Low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) (Lp[a]) levels are independently associated with atherosclerotic cardiovascular disease (ASCVD). However, the relationship between Lp(a) level, LDL-C level, and ASCVD risk at different thresholds is not well defined. METHODS: A participant-level meta-analysis of 27 658 participants enrolled in 6 placebo-controlled statin trials was performed to assess the association of LDL-C and Lp(a) levels with risk of fatal or nonfatal coronary heart disease events, stroke, or any coronary or carotid revascularization (ASCVD). The multivariable-adjusted association between baseline Lp(a) level and ASCVD risk was modeled continuously using generalized additive models, and the association between baseline LDL-C level and ASCVD risk by baseline Lp(a) level by Cox proportional hazards models with random effects. The joint association between Lp(a) level and statin-achieved LDL-C level with ASCVD risk was evaluated using Cox proportional hazards models. RESULTS: Compared with an Lp(a) level of 5 mg/dL, increasing levels of Lp(a) were log-linearly associated with ASCVD risk in statin- and placebo-treated patients. Among statin-treated individuals, those with Lp(a) level >50 mg/dL (≈125 nmol/L) had increased risk across all quartiles of achieved LDL-C level and absolute change in LDL-C level. Even among those with the lowest quartile of achieved LDL-C level (3.1–77.0 mg/dL), those with Lp(a) level >50 mg/dL had greater ASCVD risk (hazard ratio, 1.38 [95% CI, 1.06–1.79]) than those with Lp(a) level ≤50 mg/dL. The greatest risk was observed with both Lp(a) level >50 mg/dL and LDL-C level in the fourth quartile (hazard ratio, 1.90 [95% CI, 1.46–2.48]). CONCLUSIONS: These findings demonstrate the independent and additive nature of Lp(a) and LDL-C levels for ASCVD risk, and that LDL-C lowering does not fully offset Lp(a)-mediated risk.

Article Details

Journal Circulation
Volume / Issue Vol. 151, Issue 4
Published January 28, 2025
Pages 312-321
ISSN 0009-7322
Publisher Lippincott Williams & Wilkins

Journal Info

Circulation

Lippincott Williams & Wilkins

ISSN: 0009-7322 Health Sciences

Authors (13)

H

Harpreet S. Bhatia

Division of Cardiology, Department of Medicine, University of California San Diego, La Jolla.

S

Simon Wandel

Novartis Pharma AG, Basel, Switzerland (S.W., A.L., K.B.).

P

Peter Willeit

A

Anastasia Lesogor

Novartis Pharma AG, Basel, Switzerland (A.S., A.L.).

K

Keith Bailey

P

Paul M. Ridker

Brigham and Women’s Hospital, Harvard Medical School, Boston, MA (P.M.R.).

P

Paul Nestel

Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia (P.N.).

J

John Simes

NHMRC Clinical Trials Centre, University of Sydney, NSW, Australia (J.S.).

A

Andrew Tonkin

School of Public Health and Preventive Medicine, Monash University, Melbourne, Victoria, Australia (A.T.).

G

Gregory G. Schwartz

Cardiology Section, Rocky Mountain Regional VA Medical Center and University of Colorado School of Medicine, Aurora, CO (G.G.S.).

H

Helen Colhoun

MRC Human Genetics Unit, Centre for Genomic and Experimental Medicine, MRC Institute of Genetics & Molecular Medicine, Edinburgh, UK (H.C.).

C

Christoph Wanner

S

Sotirios Tsimikas